Skip to main content

Month: November 2020

Veritas Farms, Inc (OTCQB:VFRM) Reports Financial Results for Quarter Ended September 30, 2020

Fort Lauderdale, FL, Nov. 30, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Veritas Farms, Inc. (OTCQB: VFRM) (“Veritas Farms” or the “Company”), a vertically integrated agribusiness focused on the production of full spectrum hemp oil products with naturally occurring cannabinoids, is pleased to announce that the Company has reported its operating results for the quarter and nine months ended September 30, 2020, through the filing of its Quarterly Report on Form 10-Q with the SEC. The report, as well as the Company’s other periodic filings with the SEC, may be viewed at www.sec.gov.Selected Financial Highlights – Three and Nine Months Ended September 30, 2020Total Revenue of $1,466,824 in Q3-2020 vs. $1,215,810 in Q3 2019, an increase of 21%Total Revenue of $4,830,523 in 2020 period vs. $5,712,085 in 2019 period, lower by 16%Ecommerce...

Continue reading

Cidara Therapeutics to Present New Clinical Data for Rezafungin at ESICM LIVES 2020

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes place virtually Dec. 6-9, 2020.Cidara will highlight analyses from the completed Phase 2 STRIVE trial of rezafungin for treatment of candidemia and/or invasive candidiasis. Rezafungin is a novel once-weekly echinocandin currently in pivotal Phase 3 trials for the treatment and prevention of serious fungal infections. New findings from the STRIVE trial related to intensive care unit (ICU) status will be shared in the poster presentation as follows:Title: Analysis...

Continue reading

AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Patient screening and dosing ongoing in Turkey and HungaryTopline data expected in Q2 2021 for the Combination TrialDELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial evaluating its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).“In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our Combination therapy trial moving forward...

Continue reading

Vital Farms to Participate in Investor Conferences

AUSTIN, Texas, Nov. 30, 2020 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced pasture-raised foods nationwide, today announced that Russell Diez-Canseco, President and Chief Executive Officer, and Jason Dale, Chief Financial Officer and Chief Operating Officer, will present at two upcoming virtual investor conferences. The conference details include:On Thursday, December 3, 2020, Diez-Canseco and Dale will host a fireside chat at the Morgan Stanley Global Consumer & Retail Conference. The fireside chat will take place at 1:00 p.m. ET, or 12:00 p.m CT. Participants may access the live webcast under the “Events & Presentations” tab on the Vital Farms Investor Relations site: https://investors.vitalfarms.com/investor-relations. Following the discussion, a replay...

Continue reading

Assignment Agreement signed with Forte Copper on Don Gregorio Copper-Gold Project, Peru

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Candente Copper Corp. (TSX:DNT, BVL:DNT) (“Candente Copper”, “Company”) is pleased to announce that the Company has entered into an Assignment Agreement (“AA”) with Forte Copper Corp. (“Forte Copper”), on the Don Gregorio copper-gold porphyry project.The Company entered into an Option Agreement on the Don Gregorio project with Forte Copper (previously known as Plan B Minerals) in 2017. The recently signed Assignment Agreement allows Forte Copper to move ahead with applications for drilling permits.Under the Assignment and Option Agreements Forte Copper has the right to earn a 60% interest in the Don Gregorio property by completing the following terms:Making payments of US$500,000 to Candente; andDrilling 10,000 metres within three years of receiving drilling permits...

Continue reading

Conn’s, Inc. Announces Cash Tender Offer for Up To $100 Million of its 7.250% Senior Notes due 2022

THE WOODLANDS, Texas, Nov. 30, 2020 (GLOBE NEWSWIRE) — Conn’s, Inc. (NASDAQ: CONN) (“Conn’s” or the “Company”) today announced that it has commenced a cash tender offer (the “tender offer”) to purchase up to $100.0 million aggregate principal amount (as it may be increased, the “tender cap”) of its outstanding 7.250% Senior Notes due 2022 (CUSIP Nos. 208242 AB3) (the “notes”). The tender offer is being made upon the terms and subject to the conditions described in the Company’s Offer to Purchase dated November 30, 2020 (the “Offer to Purchase”). The tender offer will expire at 11:59 p.m., New York City time, on December 28, 2020, unless extended or earlier terminated by Conn’s (such time and date, the “expiration date”). Tenders of notes may be withdrawn at any time prior to 5:00 p.m., New York City time, on December 11, 2020 (the...

Continue reading

RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY

RECORDATI:  MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCYMilan, 30 November 2020 – Recordati announces that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) submission by ARS Pharmaceuticals for review of ARS-1 (known as NeffyTM in the USA), an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. On 21 September 2020 Recordati announced the signing of an exclusive license agreement with ARS Pharmaceuticals, a private U.S. company, for the commercialization of ARS-1 in 93 countries including those in the European Union.The MAA submitted to EMA includes data from multiple clinical studies showing that 1 mg of ARS-1 achieves epinephrine exposures that are similar to a 0.3 mg epinephrine...

Continue reading

RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA)

RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA)Milano, 30 novembre, 2020 – Recordati annuncia che la European Medicines Agency (EMA) ha accettato la presentazione di una Richiesta di Autorizzazione all’Immissione in Commercio da parte di ARS Pharmaceuticals per ARS-1 (Neffy™ negli Stati Uniti d’America), uno spray nasale a base di epinefrina per il trattamento in emergenza di reazioni allergiche gravi che potrebbero portare all’anafilassi. Il 21 settembre 2020 Recordati ha annunciato la firma di un accordo esclusivo di licenza con ARS Pharmaceuticals, una società farmaceutica privata basata negli Stati Uniti d’America, per la commercializzazione di ARS-1 in 93 paesi compresi quelli dell’Unione Europea.La richiesta...

Continue reading

Pasinex Announces Third Quarter 2020 Financial Results

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (The “Company” or “Pasinex”) today reports the Company’s financial and operating results for the three and nine months ended September 30, 2020.Andrew Gottwald, Chief Financial Officer of Pasinex, commented, “There were positive developments during the quarter at the Company’s Turkish joint venture including management changes, the beginning of the development of a fourth adit and the addition of the Mahyalar claim. We are also very pleased to have been able to negotiate an extension on the highly prospective Gunman project option. 2020 has proved to be a challenging year, but the Company is now positioned to drive both of these interests forward in 2021.”Highlights – Third Quarter 2020Financial and OperationalFor the three and nine months...

Continue reading

BIO-key Launches PortalGuard IDaaS (Identity-as-a-Service) Cloud Authentication Solution, Enabling Secure and Flexible Identity & Access Management

WALL, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced the launch of PortalGuard IDaaS, bringing the power of its award-winning PortalGuard identity and access management (IAM) platform to the cloud as a fully-hosted, scalable and secure identity-as-a-service (IDaaS) offering. PortalGuard IDaaS is operational, having already processed millions of authentication transactions for customers.PortalGuard IDaaS includes BIO-key’s NIST-certified device-or-server biometric authentication factors, along with fourteen other options for flexible authentication. PortalGuard IDaaS is already operational, having processed millions of authentication transactions for customers. As the demand for always-on...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.